Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
(OP:
ESAIY
)
10.08
+0.07 (+0.70%)
Streaming Delayed Price
Updated: 10:18 AM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ESAIY
< Previous
1
2
Next >
Week In Review: Eisai Enters $1.5 Billion Molecular Glues Pact With SEED
August 17, 2024
Japan’s Eisai Pharma formed a collaboration with SEED, a Pennsylvania biotech, to develop molecular glues for targeted protein degradation of disease-causing proteins. SEED is eligible to receive up to...
Via
Talk Markets
Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug
July 26, 2024
Biogen partner Eisai is planning to ask European regulators to re-examine their decision.
Via
Investor's Business Daily
The 3 Best Neuroscience Biotech Stocks to Buy Now
July 19, 2024
Given the high bar to developing good neuroscience drugs, firms that do so will likely succeed. Here are three top biotech stocks to buy now.
Via
InvestorPlace
Week In Review: Samsung Biologics Signs $1 Billion Manufacturing Contract With US Biopharma
July 06, 2024
Samsung Biologics, a Korean CDMO, signed a $1.06 billion agreement to provide manufacturing services for an unnamed US pharma. The agreement is the largest that Samsung Bio has made since it was...
Via
Talk Markets
3 Highly Rated Biotech Stocks for Your July Buy List
July 05, 2024
Discover three top-rated biotech stocks that are pushing forward the pharma and biotech revolution on Wall Street.
Via
InvestorPlace
Current Analysis: Eisai Co Ltd (ESAIY)
July 16, 2023
Eisai Co Ltd’s most recent $0.14 semi-annual dividend, paid June 12th to shareholders of record March 30th, equates to $0.28 annually and throws a yield of 1.74% as of Friday’s closing price.
Via
Talk Markets
Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
July 03, 2024
The FDA has approved Eli Lilly's Kisunla (donanemab) for early symptomatic Alzheimer's disease. Kisunla, targeting amyloid plaques, shows a significant reduction in disease progression and may reduce...
Via
Benzinga
Exposures
Product Safety
Eli Lilly Snags Long-Awaited Alzheimer's Drug Approval, Rivaling Biogen, Eisai
July 02, 2024
The company is on deck to rival Biogen and Eisai's Leqembi.
Via
Investor's Business Daily
Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst
June 11, 2024
Eli Lilly's donanemab for Alzheimer's disease garners positive FDA committee verdict, prompting analyst's bullish outlook amid comparisons to Biogen's Leqembi.
Via
Benzinga
Exposures
Product Safety
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win
June 11, 2024
An FDA panel unanimously backed Eli Lilly's Alzheimer's drug, but shares of Lilly and its rivals fell Tuesday.
Via
Investor's Business Daily
Exposures
Product Safety
Eli Lilly Rises Again, As FDA Panel Mulls Biogen-Rivaling Alzheimer's Drug
June 10, 2024
The FDA isn't bound by the committee's recommendation, but often follows it.
Via
Investor's Business Daily
Exposures
Product Safety
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
June 06, 2024
These undervalued pharma stocks to buy are worth a look because even when the economy is struggling, consumers need key medicines.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
Biogen Stock Continues Its 20% Sprint On A Twist In Alzheimer's Treatment
May 15, 2024
The company is hoping to launch an under-the-skin version of its infusion, Leqembi.
Via
Investor's Business Daily
Two Notable Biogen Drugs Walloped Sales Forecasts. Will It Be Enough To Reverse Biogen Stock's Decline?
April 24, 2024
Biogen shares have lost nearly 40% of their value since last June. Could two key sales beats help revive shares?
Via
Investor's Business Daily
Topics
Earnings
Exposures
Financial
3 Stocks Wall Street Is Ignoring (But You Shouldn’t): April Edition
April 11, 2024
Wall Street often ignores the stocks of companies with huge potential. Here are three overlooked stocks to buy.
Via
InvestorPlace
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
March 28, 2024
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.
Via
Investor's Business Daily
Exposures
Product Safety
3 Millionaire-Maker Stocks to Buy While the Gettin’ Is Good
February 12, 2024
For patient, long-term investors, these three underestimated names can easily become millionaire-maker stocks.
Via
InvestorPlace
Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million
February 11, 2024
I-Mab will become a completely US-based company, divesting itself of I-Mab Biopharma (Hangzhou), an unconsolidated affiliate. I-Mab Hangzhou will acquire rights to I-Mab’s drug assets in Greater China...
Via
Talk Markets
Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
January 23, 2024
These three companies are developing treatments for brain diseases that have a great deal of potential, making them top neuroscience stocks.
Via
InvestorPlace
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
3 Aging Population Stocks to Profit from the Boomer Generation
December 21, 2023
The elderly population of the U.S. is expected to grow tremendously in the coming years. Here are three stocks to buy for an aging population.
Via
InvestorPlace
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
November 21, 2023
Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a renewed interest in developing vaccines to combat this
Via
Benzinga
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
November 17, 2023
Biotech companies are edging closer to finding the answers behind Alzheimer's disease.
Via
Investor's Business Daily
3 Biotech Moonshots to Bet on the Future of Health
November 06, 2023
Thanks to their potential blockbuster drugs, these three biotech stocks may yield huge returns for patent investors willing to take the risk.
Via
InvestorPlace
Topics
Intellectual Property
Exposures
Intellectual Property
The 3 Best Biotech Stocks to Buy Now: September 2023
September 04, 2023
With the biotech sector looking poised to continue its rally further, investors would do well to buy these stocks to capitalize.
Via
InvestorPlace
3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes
July 30, 2023
Here are three millionaire maker drug stocks from companies whose drugs could make truly staggering profits.
Via
InvestorPlace
All Eyes On Biogen's Alzheimer's Drug, A Big Potential Payday, Ahead Of Earnings
July 24, 2023
Analysts expect Biogen to report a a decline in both profits and sales in Q2.
Via
Investor's Business Daily
Stock Futures Dip As Traders Eye Friday Jobs Report: Analyst Says Q3 Returns Hinge More On This Catalyst Than Fed Move
July 07, 2023
Via
Benzinga
Biogen's Make-Or-Break Moment Is Here In Alzheimer's Treatment
July 06, 2023
The FDA is expected to announce Thursday whether it has approved or rejected Biogen's Alzheimer's drug.
Via
Investor's Business Daily
Biogen Stock Halted As It Faces Make-Or-Break Moment For Alzheimer's Treatment
June 09, 2023
A panel of experts will debate the merits of Biogen's drug, Leqembi.
Via
Investor's Business Daily
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.